Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc (AUTL) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 24.54 M | -186,599,000 | 263.91 M | 375.38 M | 275.3 M |
| 2022 | 28.98 M | -358,180,000 | 191.6 M | 490.27 M | 425.77 M |
| 2021 | 26.25 M | -289,340,000 | 92.24 M | 405.56 M | 346.95 M |
| 2020 | 29.69 M | -99,138,000 | 84.21 M | 294.24 M | 196.98 M |
| 2019 | 30.52 M | -184,422,000 | 48.69 M | 303.53 M | 249.26 M |